LSE:AZNPharmaceuticals
AstraZeneca Readies Saphnelo Launch And Breast Cancer Push As Valuation Question Grows
AstraZeneca is preparing to launch a subcutaneous version of Saphnelo in the U.S. for systemic lupus erythematosus, aimed at broadening access to biologic treatment.
The new formulation is expected to sit directly alongside GSK's Benlysta in advanced autoimmune care.
At the same time, AstraZeneca is progressing pipeline work in ER+/HER2- breast cancer, adding to its oncology focus.
LSE:AZN recently closed at £149.18, with the share price up 47.6% over the past year and 121.2% over five...